Queen Mary University of London

Academic Institute

Sarah Finer - Chief Investigator - Queen Mary University of LondonFabiola Eto - Corresponding Applicant - Queen Mary University of LondonAlisha Angdembe - Collaborator - Queen Mary University of LondonDeborah Swinglehurst - Collaborator - Barts and the London Queen Mary's School of Medicine and DentistryMichael Barnes - Collaborator - Barts and the London Queen Mary's School of Medicine and DentistryMiriam Samuel - Collaborator - Queen Mary University of LondonNick Reynolds - Collaborator - Newcastle UniversityRafael Henkin - Collaborator - Queen Mary University of LondonRohini Mathur - Collaborator - London School of Hygiene & Tropical Medicine ( LSHTM )Sally Hull - Collaborator - Barts and the London Queen Mary's School of Medicine and DentistrySteph Taylor - Collaborator - Barts and the London Queen Mary's School of Medicine and DentistryTahania Ahmad - Collaborator - Queen Mary University of London

CPRD470

Multimorbidity describes the situation where an individual is affected by 2 or more health conditions. Studies have shown that multimorbidity is becoming more common, and the National Health Service does not currently have services designed to tackle it well. People living with multimorbidity often need to take multiple medications and require regular contact with health services. Recent research has shown that multimorbidity exists in 'clusters', with groups of common conditions (e.g. type 2 diabetes, chronic pain, and depression) often co-existing.

Our proposal seeks to deliver new knowledge on multimorbidity through the application of hypothesis-generating, data-driven analytical tools to a large-scale electronic health record dataset from a nationally-representative population. We seek to expand on previous multimorbidity research (which focuses predominantly on 30-40 common chronic conditions) to define clusters and trajectories of multimorbidity across ~200 long-term conditions. This large set of conditions have been defined through a rigorous consensus-building process and extensive review of existing validated code sets (including previously-published CPRD studies undertaken by CALIBER and the Cambridge Multimorbidity group (1–3)).

06/04/2021

Release